Markets:

Overview

News

Currencies

International

Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

2.350 +0.100 (+4.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

July 28, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

July 23, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

June 16, 2025

Capital Raised to Support Five Clinical Trials

From Alzamend Neuro, Inc.

Via GlobeNewswire

Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor’s Drink Expansion – More Stocks Inside

May 29, 2025

Via AB Newswire

Topics Economy

Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs

May 29, 2025

Via Investor Brand Network

Topics Artificial Intelligence

BioMedNewsBreaks — Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001

May 29, 2025

Via Investor Brand Network

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 29, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 07, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

March 25, 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Alzheimer’s subjects

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

March 18, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

March 11, 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in PTSD subjects

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

March 04, 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Bipolar Disorder subjects

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

February 25, 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjects

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

October 16, 2024

Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease

Via PressReach

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

October 15, 2024

October 15,

Via PressReach

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

February 19, 2025

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

October 10, 2024

October 10,

Via PressReach

Alzamend Neuro to Present at the Sequire Investor Summit

January 15, 2025

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

August 19, 2024

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease

Via PressReach

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

December 18, 2024

From Alzamend Neuro, Inc.

Via Business Wire

New Study Reveals How Classical Music Could Revolutionize Depression Care

August 12, 2024

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...

Via PressReach

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

December 12, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

November 19, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

October 16, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

October 15, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

October 10, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Issues Letter to Stockholders

August 26, 2024

From Alzamend Neuro

Via Business Wire

August 19, 2024

From Alzamend Neuro, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.